Citi analyst Andrew Kaplowitz assigned a Buy rating on Mirion Technologies yesterday and set a price target of $29.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Kaplowitz has given his Buy rating due to a combination of factors, including Mirion’s solid demand outlook in both its Nuclear and Medical businesses and a robust pipeline in key growth areas. He highlights the company’s large installed base, steady replacement and life-extension work, growing participation in SMRs and new utility-scale reactors, and the incremental, recurring contribution from the Paragon acquisition.
He also points to improving fundamentals in the Medical segment, where organic growth is expected to accelerate by 2026, helped by demographic trends, higher standards of care, and new product introductions. Management’s track record and guidance for continued margin expansion, aided by operating leverage, procurement savings, productivity initiatives such as AI, and the expectation that Paragon will shift from neutral to accretive over time, support his view of attractive upside, consistent with an expected total return in the mid-30% range.
In another report released on February 13, Robert W. Baird also maintained a Buy rating on the stock with a $29.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIR in relation to earlier this year.